{"id":1270944,"title":"Résumé du RIEM : Inhibiteurs du SGLT2 et risque d’amputation transtibiale - IRSC","sourceCode":"cihr","sourceName":"Canadian Institutes of Health Research","language":"fr","captureDate":"2026-03-27","captureTimestamp":"2026-03-27T14:23:58.632000+00:00","jobId":8,"originalUrl":"https://cihr-irsc.gc.ca/f/53777.html?wbdisable=true","snippet":"Résumé du RIEM Inhibiteurs du SGLT2 et risque d’amputation transtibiale Étude menée par le Réseau canadien pour l’étude observationnelle des médicaments ( CNODES) Quelle est la question? Les inhibiteurs du cotransporteur sodium glucose de type 2 (SGLT2) sont une nouvelle classe…","rawSnapshotUrl":"/api/snapshots/raw/1270944","browseUrl":"https://replay.healtharchive.ca/job-8/20260327142358/https://cihr-irsc.gc.ca/f/53777.html?wbdisable=true#ha_snapshot=1270944","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}